138 related articles for article (PubMed ID: 29553968)
1. Fresh Cut Versus Stored Cut Paraffin-embedded Tissue: Effect on Immunohistochemical Staining for Common Breast Cancer Markers.
Forse CL; Pinnaduwage D; Bull SB; Mulligan AM; Andrulis IL
Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):231-237. PubMed ID: 29553968
[TBL] [Abstract][Full Text] [Related]
2. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer.
Jacobs TW; Prioleau JE; Stillman IE; Schnitt SJ
J Natl Cancer Inst; 1996 Aug; 88(15):1054-9. PubMed ID: 8683636
[TBL] [Abstract][Full Text] [Related]
3. Storage Conditions and Immunoreactivity of Breast Cancer Subtyping Markers in Tissue Microarray Sections.
Omilian AR; Zirpoli GR; Cheng TD; Yao S; Stein L; Davis W; Head KL; Nair P; Khoury T; Ambrosone CB; Bshara W
Appl Immunohistochem Mol Morphol; 2020 Apr; 28(4):267-273. PubMed ID: 31205070
[TBL] [Abstract][Full Text] [Related]
4. Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study.
Grushko TA; Filiaci VL; Montag AG; Apushkin M; Gomez MJ; Monovich L; Ramirez NC; Schwab C; Kesterson JP; Seward SM; Method MW; Olopade OI; Fleming GF; Birrer MJ
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):27-35. PubMed ID: 34224438
[TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.
O'Grady A; Allen D; Happerfield L; Johnson N; Provenzano E; Pinder SE; Tee L; Gu M; Kay EW
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):489-93. PubMed ID: 20661132
[TBL] [Abstract][Full Text] [Related]
6. Loss of antigenicity in stored sections of breast cancer tissue microarrays.
Fergenbaum JH; Garcia-Closas M; Hewitt SM; Lissowska J; Sakoda LC; Sherman ME
Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):667-72. PubMed ID: 15066936
[TBL] [Abstract][Full Text] [Related]
7. Variability of immunohistochemical reactivity on stored paraffin slides.
Bertheau P; Cazals-Hatem D; Meignin V; de Roquancourt A; Vérola O; Lesourd A; Séné C; Brocheriou C; Janin A
J Clin Pathol; 1998 May; 51(5):370-4. PubMed ID: 9708203
[TBL] [Abstract][Full Text] [Related]
8. Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.
Ribelles N; Perez-Villa L; Jerez JM; Pajares B; Vicioso L; Jimenez B; de Luque V; Franco L; Gallego E; Marquez A; Alvarez M; Sanchez-Muñoz A; Perez-Rivas L; Alba E
Breast Cancer Res; 2013; 15(5):R98. PubMed ID: 24148581
[TBL] [Abstract][Full Text] [Related]
9. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
10. Effect of storage time of paraffin sections on the expression of PD-L1 (SP142) in invasive breast cancer.
He J; Wang X; Cai L; Jia Z; Liu C; Sun X; Wu S; Ding C; Zhang Z; Liu Y
Diagn Pathol; 2023 Dec; 18(1):131. PubMed ID: 38053121
[TBL] [Abstract][Full Text] [Related]
11. Quality Assessment of Proteins and RNA Following Storage in Archival Formalin-Fixed Paraffin-Embedded Human Breast Cancer Tissue Microarray Sections.
Kim K; Ylaya K; Perry C; Lee MY; Kim JW; Chung JY; Hewitt SM
Biopreserv Biobank; 2023 Oct; 21(5):493-503. PubMed ID: 36264172
[TBL] [Abstract][Full Text] [Related]
12. Molecular subtyping of male breast cancer by immunohistochemistry.
Kornegoor R; Verschuur-Maes AH; Buerger H; Hogenes MC; de Bruin PC; Oudejans JJ; van der Groep P; Hinrichs B; van Diest PJ
Mod Pathol; 2012 Mar; 25(3):398-404. PubMed ID: 22056953
[TBL] [Abstract][Full Text] [Related]
13. Effects of Hydrochloric Acid and Formic Acid Decalcification on Breast Tumor Biomarkers and HER2 Fluorescence In Situ Hybridization.
Clark BZ; Yoest JM; Onisko A; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):223-230. PubMed ID: 28877070
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
15. Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.
Chung A; Choi M; Han BC; Bose S; Zhang X; Medina-Kauwe L; Sims J; Murali R; Taguiam M; Varda M; Schiff R; Giuliano A; Cui X
Clin Breast Cancer; 2015 Dec; 15(6):448-457.e2. PubMed ID: 26248960
[TBL] [Abstract][Full Text] [Related]
16. Comparison of p53 immunoreactivity in fresh-cut versus stored slides with and without microwave heating.
Shin HJ; Kalapurakal SK; Lee JJ; Ro JY; Hong WK; Lee JS
Mod Pathol; 1997 Mar; 10(3):224-30. PubMed ID: 9071730
[TBL] [Abstract][Full Text] [Related]
17. Strong association of epidermal growth factor receptor status with breast cancer FDG uptake.
Lee J; Lee EJ; Moon SH; Kim S; Hyun SH; Cho YS; Choi JY; Kim BT; Lee KH
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1438-1447. PubMed ID: 28488029
[TBL] [Abstract][Full Text] [Related]
18. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer.
Guler G; Huebner K; Himmetoglu C; Jimenez RE; Costinean S; Volinia S; Pilarski RT; Hayran M; Shapiro CL
Cancer; 2009 Feb; 115(4):899-908. PubMed ID: 19130459
[TBL] [Abstract][Full Text] [Related]
19. Frequency of breast cancer subtypes among African American women in the AMBER consortium.
Allott EH; Geradts J; Cohen SM; Khoury T; Zirpoli GR; Bshara W; Davis W; Omilian A; Nair P; Ondracek RP; Cheng TD; Miller CR; Hwang H; Thorne LB; O'Connor S; Bethea TN; Bell ME; Hu Z; Li Y; Kirk EL; Sun X; Ruiz-Narvaez EA; Perou CM; Palmer JR; Olshan AF; Ambrosone CB; Troester MA
Breast Cancer Res; 2018 Feb; 20(1):12. PubMed ID: 29409530
[TBL] [Abstract][Full Text] [Related]
20. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
